Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $44.2857.

A number of equities research analysts have recently weighed in on ZBIO shares. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Friday, March 27th. Finally, Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th.

Insider Activity at Zenas BioPharma

In related news, Director Hongbo Lu acquired 3,768 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the completion of the acquisition, the director owned 426,736 shares of the company’s stock, valued at $7,950,091.68. This trade represents a 0.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Fairmount Funds Management Llc acquired 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was bought at an average price of $20.00 per share, with a total value of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares of the company’s stock, valued at $47,180,500. The trade was a 6.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 273,768 shares of company stock worth $5,150,198. 22.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP increased its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma in the third quarter valued at about $30,000. GF Fund Management CO. LTD. bought a new stake in Zenas BioPharma in the fourth quarter valued at about $38,000. BNP Paribas Financial Markets increased its holdings in Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares during the last quarter. Finally, CWM LLC increased its holdings in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares during the last quarter.

Zenas BioPharma Trading Down 5.5%

ZBIO stock opened at $18.71 on Tuesday. The company has a market cap of $1.18 billion, a P/E ratio of -2.21 and a beta of -0.71. Zenas BioPharma has a twelve month low of $8.91 and a twelve month high of $44.60. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The business has a fifty day moving average of $19.38 and a 200-day moving average of $24.43.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same period in the prior year, the company posted ($0.80) EPS. As a group, equities research analysts expect that Zenas BioPharma will post -4.47 EPS for the current year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.